{"id":37915,"date":"2025-07-25T12:11:34","date_gmt":"2025-07-25T04:11:34","guid":{"rendered":"https:\/\/flcube.com\/?p=37915"},"modified":"2025-07-25T12:11:35","modified_gmt":"2025-07-25T04:11:35","slug":"ipsens-cabometyx-approved-by-european-commission-for-neuroendocrine-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37915","title":{"rendered":"Ipsen’s Cabometyx Approved by European Commission for Neuroendocrine Tumors"},"content":{"rendered":"\n

France-based pharmaceutical company Ipsen S.A. (EPA: IPN<\/a>, OTCMKTS: IPSEY<\/a>) announced that its anticancer drug Cabometyx (cabozantinib) has been approved by the European Commission for the treatment of adult patients with unresectable or metastatic pancreatic and extra-pancreatic neuroendocrine tumors (pNET and epNET). This approval is for patients who have experienced disease progression after at least one prior systemic therapy that does not include somatostatin analogues. This marks the first EU approval of a systemic treatment for this patient population.<\/p>\n\n\n\n

Drug Mechanism and Previous Approvals<\/strong>
Cabometyx is an oral small-molecule tyrosine kinase inhibitor targeting multiple key pathways, including VEGFR, MET, and RET. It has already been approved in multiple countries for treating renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
The approval is based on results from the CABINET Phase III clinical trial. In the pNET population, Cabometyx reduced the risk of disease progression or death by 77% compared to placebo, extending median progression-free survival (PFS) from 4.4 months to 13.8 months (HR=0.23, p<0.001). In the epNET population, it reduced the risk by 62%, with median PFS extended from 3.9 months to 8.4 months (HR=0.38, p<0.001). Overall survival data remain immature. The safety profile of Cabometyx was consistent with previous findings, with no new safety signals observed.<\/p>\n\n\n\n

Significance for Patients<\/strong>
Treatment options for patients with progressive neuroendocrine tumors have been limited, especially for those with lung-origin NETs who have long lacked approved therapies. This approval provides a new treatment option for this challenging clinical setting and significantly broadens the indications for Cabometyx. It represents an important advancement in the treatment of neuroendocrine tumors.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that its anticancer drug Cabometyx…<\/p>\n","protected":false},"author":1,"featured_media":37917,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,880,519,881,15],"class_list":["post-37915","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-epa-ipn","tag-ipsen-s-a","tag-otcmkts-ipsey","tag-product-approvals"],"yoast_head":"\nIpsen's Cabometyx Approved by European Commission for Neuroendocrine Tumors - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that its anticancer drug Cabometyx (cabozantinib) has been approved by the European Commission for the treatment of adult patients with unresectable or metastatic pancreatic and extra-pancreatic neuroendocrine tumors (pNET and epNET). This approval is for patients who have experienced disease progression after at least one prior systemic therapy that does not include somatostatin analogues. This marks the first EU approval of a systemic treatment for this patient population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37915\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen's Cabometyx Approved by European Commission for Neuroendocrine Tumors\" \/>\n<meta property=\"og:description\" content=\"France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that its anticancer drug Cabometyx (cabozantinib) has been approved by the European Commission for the treatment of adult patients with unresectable or metastatic pancreatic and extra-pancreatic neuroendocrine tumors (pNET and epNET). This approval is for patients who have experienced disease progression after at least one prior systemic therapy that does not include somatostatin analogues. This marks the first EU approval of a systemic treatment for this patient population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37915\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-25T04:11:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-25T04:11:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2501.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37915#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37915\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ipsen’s Cabometyx Approved by European Commission for Neuroendocrine Tumors\",\"datePublished\":\"2025-07-25T04:11:34+00:00\",\"dateModified\":\"2025-07-25T04:11:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37915\"},\"wordCount\":275,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37915#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2501.webp\",\"keywords\":[\"Cancer\",\"EPA: IPN\",\"Ipsen S.A.\",\"OTCMKTS: IPSEY\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37915#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37915\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37915\",\"name\":\"Ipsen's Cabometyx Approved by European Commission for Neuroendocrine Tumors - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37915#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37915#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2501.webp\",\"datePublished\":\"2025-07-25T04:11:34+00:00\",\"dateModified\":\"2025-07-25T04:11:35+00:00\",\"description\":\"France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that its anticancer drug Cabometyx (cabozantinib) has been approved by the European Commission for the treatment of adult patients with unresectable or metastatic pancreatic and extra-pancreatic neuroendocrine tumors (pNET and epNET). This approval is for patients who have experienced disease progression after at least one prior systemic therapy that does not include somatostatin analogues. This marks the first EU approval of a systemic treatment for this patient population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37915#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37915\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37915#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2501.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2501.webp\",\"width\":1080,\"height\":608,\"caption\":\"Ipsen's Cabometyx Approved by European Commission for Neuroendocrine Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37915#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen’s Cabometyx Approved by European Commission for Neuroendocrine Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ipsen's Cabometyx Approved by European Commission for Neuroendocrine Tumors - Insight, China's Pharmaceutical Industry","description":"France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that its anticancer drug Cabometyx (cabozantinib) has been approved by the European Commission for the treatment of adult patients with unresectable or metastatic pancreatic and extra-pancreatic neuroendocrine tumors (pNET and epNET). This approval is for patients who have experienced disease progression after at least one prior systemic therapy that does not include somatostatin analogues. This marks the first EU approval of a systemic treatment for this patient population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37915","og_locale":"en_US","og_type":"article","og_title":"Ipsen's Cabometyx Approved by European Commission for Neuroendocrine Tumors","og_description":"France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that its anticancer drug Cabometyx (cabozantinib) has been approved by the European Commission for the treatment of adult patients with unresectable or metastatic pancreatic and extra-pancreatic neuroendocrine tumors (pNET and epNET). This approval is for patients who have experienced disease progression after at least one prior systemic therapy that does not include somatostatin analogues. This marks the first EU approval of a systemic treatment for this patient population.","og_url":"https:\/\/flcube.com\/?p=37915","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-25T04:11:34+00:00","article_modified_time":"2025-07-25T04:11:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2501.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37915#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37915"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ipsen’s Cabometyx Approved by European Commission for Neuroendocrine Tumors","datePublished":"2025-07-25T04:11:34+00:00","dateModified":"2025-07-25T04:11:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37915"},"wordCount":275,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37915#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2501.webp","keywords":["Cancer","EPA: IPN","Ipsen S.A.","OTCMKTS: IPSEY","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37915#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37915","url":"https:\/\/flcube.com\/?p=37915","name":"Ipsen's Cabometyx Approved by European Commission for Neuroendocrine Tumors - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37915#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37915#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2501.webp","datePublished":"2025-07-25T04:11:34+00:00","dateModified":"2025-07-25T04:11:35+00:00","description":"France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that its anticancer drug Cabometyx (cabozantinib) has been approved by the European Commission for the treatment of adult patients with unresectable or metastatic pancreatic and extra-pancreatic neuroendocrine tumors (pNET and epNET). This approval is for patients who have experienced disease progression after at least one prior systemic therapy that does not include somatostatin analogues. This marks the first EU approval of a systemic treatment for this patient population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37915#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37915"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37915#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2501.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2501.webp","width":1080,"height":608,"caption":"Ipsen's Cabometyx Approved by European Commission for Neuroendocrine Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37915#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ipsen’s Cabometyx Approved by European Commission for Neuroendocrine Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2501.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37915"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37915\/revisions"}],"predecessor-version":[{"id":37918,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37915\/revisions\/37918"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37917"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}